Novel Approaches and Targeted Therapies in AML
Session VI at iwAL 2018 saw targeted therapies and novel approaches in AML discussed, with e-learning webinars from Jorge Cortes, MD, Andrew Wei, MBBS, PhD, FRACP, FRCPA, Mark Levis, MD, PhD, Jeffrey Lancet, MD, Stephane de Botton, MD, PhD, Martin Tallman, MD. Various therapies came into focus, including BCL-2 inhibitors, FLT3+ targets, IDH inhibitors, liposomal formations and a novel SMO inhibitor.
Presentations
University of Texas MD Anderson Cancer Center, Houston, TX
Jorge Cortes, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, talks about the novel SMO inhibitor glasdegib.
Monash University, Victoria, Australia
Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Monash University, Victoria, Australia, discusses using BCL-2 inhibitors as part of combination therapies.
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, outlines the new therapies for FLT3+ AML.
Moffitt Cancer Center, Tampa, FL
Jeffrey Lancet, MD, from the Moffitt Cancer Center, Tampa, FL, talks about exciting liposomal advances in AML.
Gustave Roussy Institute, Paris, France
Stephane de Botton, MD, PhD, from the Gustave Roussy Institute, Paris, France, discusses IDH1 and IDH2 inhibitors.
Memorial Sloan Kettering Cancer Center, New York, NY
Martin Tallman, MD, Memorial Sloan Kettering Cancer Center, New York, NY, presents on incorporating emerging therapies into the treatment of AML.
